Global Cervical Cancer Therapeutics Market 2019-2023
SKU ID : TNV-14253032 | Publishing Date : 08-May-2019 | No. of pages : 124
Detailed TOC of Global Cervical Cancer Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: PIPELINE ANALYSIS
PART 07: MARKET SEGMENTATION BY TYPE
Market segmentation by type
Comparison by type
Drugs - Market size and forecast 2018-2023
Vaccines - Market size and forecast 2018-2023
Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 14: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Bristol-Myers Squibb Co.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Merck & Co. Inc.
Novartis AG
PART 15: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Some of the late-stage molecules for cervical cancer
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Drugs - Year-over-year growth 2019-2023 (%)
Exhibit 22: Vaccines - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Vaccines - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 49: Bristol-Myers Squibb Co. - Business segments
Exhibit 50: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 51: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 52: Bristol-Myers Squibb Co. - Key offerings
Exhibit 53: Bristol-Myers Squibb Co. - Key customers
Exhibit 54: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 55: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 56: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 57: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 58: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 59: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 60: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 61: GlaxoSmithKline Plc - Vendor overview
Exhibit 62: GlaxoSmithKline Plc - Business segments
Exhibit 63: GlaxoSmithKline Plc - Organizational developments
Exhibit 64: GlaxoSmithKline Plc - Geographic focus
Exhibit 65: GlaxoSmithKline Plc - Segment focus
Exhibit 66: GlaxoSmithKline Plc - Key offerings
Exhibit 67: GlaxoSmithKline Plc - Key customers
Exhibit 68: Merck & Co. Inc. - Vendor overview
Exhibit 69: Merck & Co. Inc. - Business segments
Exhibit 70: Merck & Co. Inc. - Organizational developments
Exhibit 71: Merck & Co. Inc. - Geographic focus
Exhibit 72: Merck & Co. Inc. - Segment focus
Exhibit 73: Merck & Co. Inc. - Key offerings
Exhibit 74: Merck & Co. Inc. - Key customers
Exhibit 75: Novartis AG - Vendor overview
Exhibit 76: Novartis AG - Business segments
Exhibit 77: Novartis AG - Organizational developments
Exhibit 78: Novartis AG - Geographic focus
Exhibit 79: Novartis AG - Segment focus
Exhibit 80: Novartis AG - Key offerings
Exhibit 81: Novartis AG - Key customers
Exhibit 82: Validation techniques employed for market sizing
Exhibit 83: Definition of market positioning of vendors
Keyplayers in Global Cervical Cancer Therapeutics Market 2019-2023
Bristol-Myers Squibb Co.F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Merck & Co. Inc.
Novartis AG